Incredible Buzz Hosts Motiva FDA Approval Celebration Event..."Sustaining Strong Market Dominance and Competitive Advantage"

Incredible Buzz's affiliate Motiva Korea held an event to celebrate the approval of Motiva breast implants, exclusively supplied domestically, by the U.S. Food and Drug Administration (FDA), the company announced on the 18th. In September, the FDA approved Motiva's 'Smooth Silk Ergonomics' and 'Smooth Silk Round' for primary breast augmentation and revision surgeries.

Juan Jose Cachonquiros, CEO and founder of Motiva manufacturer Establishment Labs, is holding a celebration event for Motiva's approval by the U.S. Food and Drug Administration (FDA). Photo by Incredible Buzz

The event was held for the first time worldwide in Seoul, South Korea. Approximately 50 domestic medical professionals using Motiva attended, including Juan Jose Cachon Quiros, CEO of Motiva manufacturer Establishment Labs Holdings Inc., and Lim Shin-young, CEO of Motiva Korea.

At the event, Motiva explained the preparation process for FDA approval and shared its global strategy, vision, and values. The company stated that Motiva has rapidly demonstrated a success story in the breast implant market, which was previously dominated by global conglomerates, through its competitive sales and marketing strategies.

In particular, success in the Korean market, which is regarded as having the most advanced medical technology in aesthetics and plastic surgery, has driven Motiva's growth. Motiva holds an overwhelming first place with about 50% market share domestically.

Prior to this event, Motiva held a ceremony on the 15th in Beijing, China, to celebrate the first anniversary of its approval and brand growth. The event highlighted Motiva's achievements in China over the past year and brought together Korean and Chinese medical professionals to exchange surgical cases and information using Motiva breast implants.

Human Wellness, the largest shareholder of Incredible Buzz, has secured exclusive supply rights for Motiva in Korea and China and is conducting business through Motiva Korea and Motiva China, respectively. Additionally, Lim Shin-young, CEO of Incredible Buzz, concurrently serves as the CEO of both companies.

CEO Lim said, "With Motiva's FDA approval, we have not only proven safety but also gained a clear differentiation point for expanding domestic and international markets. We will strive to make Motiva China the second Motiva Korea by benchmarking the success story in the domestic breast implant market, where we have already demonstrated solid market dominance."

Meanwhile, Incredible Buzz acquired a 21.9% stake in Motiva Korea through its subsidiary Incredible Daebu in September. The company plans to establish a system that can create synergy between Incredible Buzz and Motiva businesses in Korea and China, including further equity expansion in the future.